John Xu

1.9k total citations
24 papers, 560 citations indexed

About

John Xu is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, John Xu has authored 24 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Endocrinology, Diabetes and Metabolism, 11 papers in Surgery and 8 papers in Molecular Biology. Recurrent topics in John Xu's work include Diabetes Treatment and Management (16 papers), Pancreatic function and diabetes (10 papers) and Diabetes Management and Research (10 papers). John Xu is often cited by papers focused on Diabetes Treatment and Management (16 papers), Pancreatic function and diabetes (10 papers) and Diabetes Management and Research (10 papers). John Xu collaborates with scholars based in United States, Sweden and Germany. John Xu's co-authors include C. David Sjöström, Paresh Dandona, Nevin Ajluni, Frederik Persson, Peter J. Greasley, Hiddo J.L. Heerspink, S. Petrykiv, Moshe Phillip, Chantal Mathieu and Fredrik Thorén and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Diabetes Care.

In The Last Decade

John Xu

22 papers receiving 544 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Xu United States	14	406	257	171	95	62	24	560
Alessandra Scamporrino Italy	15	197 0.5×	190 0.7×	166 1.0×	27 0.3×	38 0.6×	36	583
Norihisa Osawa Japan	10	212 0.5×	122 0.5×	128 0.7×	56 0.6×	58 0.9×	14	495
Nobuko Maruyama Japan	12	566 1.4×	321 1.2×	254 1.5×	67 0.7×	11 0.2×	14	618
Xuesi Wan China	14	162 0.4×	120 0.5×	174 1.0×	19 0.2×	39 0.6×	23	438
M. France United Kingdom	9	108 0.3×	143 0.6×	81 0.5×	31 0.3×	39 0.6×	16	345
Irina Kline United States	8	350 0.9×	177 0.7×	241 1.4×	59 0.6×	7 0.1×	13	539
Christina Stahre Sweden	9	414 1.0×	151 0.6×	174 1.0×	18 0.2×	14 0.2×	12	524
S. Durán‐García Spain	11	978 2.4×	441 1.7×	497 2.9×	35 0.4×	28 0.5×	20	1.1k
Lijun Ma China	6	164 0.4×	96 0.4×	155 0.9×	80 0.8×	16 0.3×	7	487

Countries citing papers authored by John Xu

Since Specialization

Citations

This map shows the geographic impact of John Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Xu more than expected).

Fields of papers citing papers by John Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Xu. The network helps show where John Xu may publish in the future.

Co-authorship network of co-authors of John Xu

This figure shows the co-authorship network connecting the top 25 collaborators of John Xu. A scholar is included among the top collaborators of John Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Xu. John Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pleasants, Roy A., Mandeep Jassal, John Xu, et al.. (2025). A Randomized, Double-Blind Crossover Study of Change in Post-Dose Lung Function with Hydrofluoroolefin-1234ze, a Next-Generation Propellant for Metered Dose Inhalers, in Participants with Asthma. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 38(5). 275–283.

Jiang, Wenbo, Xiaoxia Chu, Xue Li, et al.. (2024). GenSci120, a humanized PD-1 agonistic monoclonal antibody, enhances the binding of both PD-L1 and PD-L2 to PD-1, and mitigates the symptoms of GVHD in a mouse model. The Journal of Immunology. 212(1_Supplement). 0718_6289–0718_6289.

Groop, Per‐Henrik, Paresh Dandona, Moshe Phillip, et al.. (2020). Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. The Lancet Diabetes & Endocrinology. 8(10). 845–854. 53 indexed citations

Aberle, Jens, Sebastian Schmid, Christoph Terkamp, et al.. (2020). Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes. Scientific Reports. 10(1). 22396–22396. 33 indexed citations

Phillip, Moshe, Chantal Mathieu, Marcus Lind, et al.. (2020). Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT ‐1 and ‐2 studies. Diabetes Obesity and Metabolism. 23(2). 549–560. 26 indexed citations

Mathieu, Chantal, Paresh Dandona, Andreas L. Birkenfeld, et al.. (2020). Benefit/risk profile of dapagliflozin 5 mg in the DEPICT ‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m ². Diabetes Obesity and Metabolism. 22(11). 2151–2160. 24 indexed citations

Mathieu, Chantal, Paresh Dandona, Moshe Phillip, et al.. (2019). SAT-LB025 Analysis of Benefit/Risk in the Subgroup of Patients with BMI of >=27 Kg/m2 in the Dapagliflozin DEPICT-1 and -2 Trials in Type 1 Diabetes. Journal of the Endocrine Society. 3(Supplement_1). 8 indexed citations

Dandona, Paresh, Chantal Mathieu, Moshe Phillip, et al.. (2019). 1231-P: Dapagliflozin (DAPA) in Type 1 Diabetes (T1D): Pooled Outcomes from DEPICT-1 and -2. Diabetes. 68(Supplement_1). 2 indexed citations

Mathieu, Chantal, Paresh Dandona, Moshe Phillip, et al.. (2018). Glucose Variables in T1D Studies with Dapagliflozin—Pooled Analysis of Continuous Glucose Monitoring Data from DEPICT-1 and 2. Diabetes. 67(Supplement_1). 1 indexed citations

10.

Dandona, Paresh, Chantal Mathieu, Moshe Phillip, et al.. (2018). Long-Term Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes—The DEPICT-1 Study. Diabetes. 67(Supplement_1). 10 indexed citations

11.

Bays, Harold, Peter Sartipy, John Xu, C. David Sjöström, & James Underberg. (2017). Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. Journal of clinical lipidology. 11(2). 450–458.e1. 27 indexed citations

12.

Kosiborod, Mikhail, Ingrid Gause‐Nilsson, John Xu, Christian Sonesson, & Eva Johnsson. (2017). Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. Journal of Diabetes and its Complications. 31(7). 1215–1221. 31 indexed citations

13.

Rudofsky, Gottfried, et al.. (2017). Frequency of Genital Infections According to Body Mass Index in Dapagliflozin-treated Patients with Type 2 Diabetes Mellitus. 4(1). e1–e4. 3 indexed citations

14.

Ajluni, Nevin & John Xu. (2016). Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program. Journal of Diabetes & Metabolism. 7(3). 40 indexed citations

15.

Leiter, Lawrence A., William T. Cefalu, Tjerk W.A. de Bruin, et al.. (2016). Long‐term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Obesity and Metabolism. 18(8). 766–774. 29 indexed citations

16.

Gummesson, Anders, Haiyan Li, Michael Gillen, et al.. (2014). Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Chinese Subjects. Clinical Drug Investigation. 34(11). 763–772. 4 indexed citations

17.

Hyams, David M., Arlene Chan, Raymond Snyder, et al.. (2013). Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. Investigational New Drugs. 31(5). 1345–1354. 33 indexed citations

18.

LoRusso, Patricia, Anthony F. Shields, Shirish M. Gadgeel, et al.. (2010). Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. Investigational New Drugs. 29(6). 1395–1405. 18 indexed citations

19.

Shields, Anthony F., Elisabeth I. Heath, Pamela DeLuca, et al.. (2007). AZD2171 in combination with various anticancer regimens: Follow-up results of a phase I multi-cohort study. Journal of Clinical Oncology. 25(18_suppl). 3544–3544. 7 indexed citations

20.

Berger, William E., Paul Y. Qaqundah, Kathryn Blake, et al.. (2005). Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze. The Journal of Pediatrics. 146(1). 91–95. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact